OncoResponse Announces Initiation of Phase 1/2 Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, today announced the dosing of the first participant in the Phase 1/2 trial of OR502, a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2) antibody that rescues innate and adaptive immune responses from LILRB2 mediated immune suppression. This Phase 1/2 study is designed to determine the safety, tolerability, and preliminary anti-tumor activity of OR502 administered as a monotherapy and in combination with anti-PD-1 in subjects with advanced solid tumors.

“Initiating this study in cancer patients reflects our continued commitment to advancing programs that have the greatest potential to improve outcomes for patients undergoing cancer treatment,” said Clifford Stocks, Chief Executive Officer of OncoResponse.

“OR502 binds to LILRB2 in a unique way to reverse immunosuppression in cancer and offers a potential treatment option to patients who have otherwise struggled with CPI therapy effectiveness,” said Kamal Puri, PhD, Chief Scientific Officer of OncoResponse.  “OncoResponse has spent years devising strategies to block or reprogram tumor associated macrophages to drive anti-tumor activity. We are excited by the vast promise of OR502 in the LILRB2 target space with preclinical data showing superiority to other clinically validated anti-LILRB2 antibodies.”


Leave a Reply

Your email address will not be published. Required fields are marked *